Floatz logo

[18f]f-resca-rt4

Lung Diseases

RenJi HospitalradiopharmaceuticalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Lung Diseases cohort.

Asset / SponsorPhaseRating
Carboplatin
Jiangmen Central Hospital
Phase 3BB
Ivacaftor
University of British Columbia
Phase 3BB
Theophylline
NCIC Clinical Trials Group
Phase 3BB
Lumacaftor
Vertex Pharmaceuticals Incorporated
Phase 3BB
Pembrolizumab
Sarah Goldberg
Phase 3B

View all 50 →

Same molecule, other indications

[18f]f-resca-rt4 is also rated in:

urothelial carcinomaDormant
B
Indicative ·
57 / 100
View asset →
nasopharyngeal carcinomaDormant
B
Indicative ·
57 / 100
View asset →
carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →